Association of Lipoprotein(a) with Coronary Artery Disease in Peripheral Artery Disease Patients

Background and Aims : To evaluate the relationship of lipoprotein(a) [Lp(a)] level with coronary artery disease (CAD) in patients with peripheral artery disease (PAD).Methods: The study included 285 patients with PAD. The patients were divided into two groups depending on presence of CAD. The group with CAD consisted of 208 patients and the group without CAD contained 77 patients. The levels of lipids, Lp(a), C-reactive protein (CRP) were measured in serum.Results: The groups with and without CAD were comparable by age and sex. In group with CAD the frequency of hypertension, type 2 diabetes, smoking was higher than in the group without CAD. The level of Lp(a) was significantly higher in patients with CAD than in those without CAD: 36 [15; 80] vs. 30 [10; 49] mg/dL, p=0.01. Prevalence of Lp(a) ≥50 mg/dL [hyperlipoproteinemia(a)] was significantly higher in patients with both PAD and CAD comparing to patients with PAD but without CAD: 78 (38%) vs. 18 (23%), p=0.03. The odds ratio of CAD in PAD patients in the presence of Lp(a) level ≥50 mg/dL was 2.0 (95% confidence interval, 1.1-3.6, p=0.03). There were no differences between groups in lipids and CRP level. In logistic regression analysis adjusted for hypertension, type 2 diabetes and smoking, Lp(a) was an independent predictor of CAD in PAD patients.Conclusions: In PAD patients Lp(a) concentration and prevalence of hyperlipoproteinemia(a) were higher in patients with CAD than without CAD. Lp(a) level is an independent predictor of CAD in PAD patients. Background and Aims : To evaluate the relationship of lipoprotein(a) [Lp(a)] level with coronary artery disease (CAD) in patients with peripheral artery disease (PAD). Methods: The study included 285 patients with PAD. The patients were divided into two groups depending on presence of CAD. The group with CAD consisted of 208 patients and the group without CAD contained 77 patients. The levels of lipids, Lp(a), C-reactive protein (CRP) were measured in serum. Results: The groups with and without CAD were comparable by age and sex. In group with CAD the frequency of hypertension, type 2 diabetes, smoking was higher than in the group without CAD. The level of Lp(a) was significantly higher in patients with CAD than in those without CAD: 36 [15; 80] vs. 30 [10; 49] mg/dL, p=0.01. Prevalence of Lp(a) ≥50 mg/dL [hyperlipoproteinemia(a)] was significantly higher in patients with both PAD and CAD comparing to patients with PAD but without CAD: 78 (38%) vs. 18 (23%), p=0.03. The odds ratio of CAD in PAD patients in the presence of Lp(a) level ≥50 mg/dL was 2.0 (95% confidence interval, 1.1-3.6, p=0.03). There were no differences between groups in lipids and CRP level. In logistic regression analysis adjusted for hypertension, type 2 diabetes and smoking, Lp(a) was an independent predictor of CAD in PAD patients. Conclusions: In PAD patients Lp(a) concentration and prevalence of hyperlipoproteinemia(a) were higher in patients with CAD than without CAD. Lp(a) level is an independent predictor of CAD in PAD patients.